January 17th, 2024: Ratio Therapeutics Announces $50M Series B ...

Jan 17, 2024 · Boston-Based Radiopharmaceutical Company Brings Total Financing to More Than $90Million Since 2021 Launch. BOSTON, January 17, 2024 – Ratio Therapeutics Inc. …

CouponFollow Extension

$50
OFF

January 17th, 2024: Ratio Therapeutics Announces $50M Series B ...

6 days from now

Jan 17, 2024 · Boston-Based Radiopharmaceutical Company Brings Total Financing to More Than $90Million Since 2021 Launch. BOSTON, January 17, 2024 – Ratio Therapeutics Inc. …

ratiotx.com

$50
OFF

Ratio Therapeutics Announces $50M Series B Financing To …

6 days from now

Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the treatment and monitoring of …

yahoo.com

$50
OFF

Ratio Therapeutics Announces $50M Series B Financing To …

6 days from now

Jan 17, 2024 · Boston-Based Radiopharmaceutical Company Brings Total Financing to More Than $90 Million Since 2021 Launch. BOSTON, Jan. 17, 2024 /PRNewswire/ -- Ratio …

biospace.com

$50
OFF

Ratio Therapeutics Raises $50M In Series B Financing

6 days from now

Jan 17, 2024 · In July 2023, Ratio began studying its FAP-targeted, Cu-64-labeled radiopharmaceutical, RTX-1363S, in a Phase I trial in healthy volunteers. According to a …

precisionmedicineonline.com

$50
OFF

Ratio Therapeutics Secures Funds For Cancer Radiotherapies

6 days from now

Jan 18, 2024 · Ratio Therapeutics has secured $50m in a Series B financing round, a significant move aimed at advancing radiotherapies for cancer treatment.

proz2020.com

$20
OFF

Ratio Therapeutics Announces $20M Series A Financing To …

6 days from now

Feb 1, 2023 · Boston-Based Pharmaceutical Company Brings Total Financing to More Than $40 Million since 2022 LaunchDr. Susan K. Whoriskey, Ph.D., to Join the Co...

businessinsider.com

$50
OFF

Ratio Therapeutics Announces $50M Series B Financing To …

6 days from now

Jan 17, 2024 · Boston-Based Radiopharmaceutical Company Brings Total Financing to More Than $90 Million Since 2021 Launch. BOSTON, MA, USA I January 17, 2024 I Ratio …

pipelinereview.com

$20
OFF

News - Ratio Therapeutics

6 days from now

February 1, 2023: Ratio Therapeutics Announces $20M Series A Financing to Advance Targeted Radiotherapies for Cancer Treatment. Boston-Based Pharmaceutical Company Brings Total …

ratiotx.com

$50000000
OFF

Series B - Ratio Therapeutics - 2024-01-17 - Crunchbase

6 days from now

Jan 17, 2024 · Ratio Therapeutics raised $50000000 on 2024-01-17 in Series B. Search Crunchbase. ... Ratio Therapeutics secures $50 million in Series B financing . ... Ratio …

crunchbase.com

$20
OFF

Ratio Therapeutics Announces $20M Series A Financing To …

6 days from now

BOSTON, Feb. 1, 2023 /PRNewswire/ -- Ratio Therapeutics Inc., a pharmaceutical company specializing in the development of targeted radiotherapeutics for the treatment of cancer, …

prnewswire.com

$750
OFF

Ratio Nets Potential $750M Radioligand Cancer Deal With Novartis

6 days from now

4 days ago · Ratio Therapeutics has inked an exclusive worldwide agreement potentially worth $745M with Novartis Pharma AG. The collaboration leverages Ratio’s radioligand therapy …

insideprecisionmedicine.com

$745
OFF

Novartis Strikes Radiopharma Deal With Ratio Worth Up To $745M

6 days from now

4 days ago · Novartis and Ratio Therapeutics announced a collaboration deal worth up to $745 million, focusing on SSTR2 radiotherapeutic cancer treatment. Ratio will receive an …

endpts.com

$50
OFF

Invest In Ratio Therapeutics Stock | Buy Pre-IPO Shares - EquityZen

6 days from now

Jun 4, 2024 · Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment. biospace • Jun 04, 2024. ... Accredited investors can …

equityzen.com

FAQs about January 17th, 2024: Ratio Therapeutics Announces $50M Series B ... Coupon?

What does ratio Therapeutics do?

Developing best-in-class radiopharmaceuticals for cancer patients A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers. ...

What is the therapeutic ratio in radiotherapy for cancer treatment?

The therapeutic ratio in radiotherapy for cancer treatment is determined by the maximum radiation dose for killing cancer cells and the minimum radiation dose causing acute or late morbidity in cells of normal tissues. Both of these parameters have sigmoidal dose–response curves. ...

Can targeted radiation therapy improve the radiation therapeutic ratio?

In the era of precision medicine, radiation medicine is currently focused on the precise delivery of highly conformal radiation treatments. However, the tremendous developments in targeted therapy are yet to fulfill their full promise and arguably have the potential to dramatically enhance the radiation therapeutic ratio. ...

What is Novartis partnering with ratio Therapeutics?

Novartis has teamed up with Ratio Therapeutics in a $745m licensing and collaboration agreement to advance radiopharmaceutical therapies. ...

What is radiopharmaceutical therapy?

Radiopharmaceutical therapy – which involves targeting cancer cells with a radioactive drug consisting of a radioactive atom combined with a cell-targeting molecule – has seen substantial growth in recent years. ...

What is ratio's R&D platform?

Ratio's proprietary R&D platforms, Trillium™ and Macropa™, enable the imaging, discovery, and advancement of novel radiopharmaceuticals. Built to be the radiopharmaceuticals discovery and development partner of choice, Ratio currently collaborates with Bayer and Lantheus. ...